Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
National Institute of Mental Health (NIMH)
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently meeting DSM-V Criteria for a Major Depressive Episode of at least mild-moderate severity
Aged 18-85
Ability and willingness to attend study visits and complete study assessments
You may not be if
Presence of medical conditions at screening that may affect the safe administration of psilocybin (including, but not limited to: AST/ALT \> 150, QTc \> 450ms, MELD \> 9)
Depression deemed secondary to a severe medical condition
Recent use of any classical psychedelic drug or MDMA
Recent use of any interventional psychiatric treatment (including: ECT, ketamine, esketamine, TMS)
Intention to begin any new treatment for depression prior to primary outcome determination
Use of any excluded medication
Active substance use disorder
Presence of any psychiatric condition that may interfere with the safe administration of psilocybin
Active suicidal ideation
Clareo Health | Psilocybin for Major Depressive Disorder
